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rent 20%) in the population. CONCLUSIONS: The
model suggests that annual PSA screening of male popu-
lation for prostate cancer is extremely cost-effective,
given current data. Further research into outcomes of
prostate cancer is needed to estimate cost-effectiveness of
screening in various subpopulations. In particular, given
the long clinical progression of prostate cancer, more re-
search is required into outcomes and cost-effectiveness in
relatively healthy patients versus those burdened by seri-
ous co-morbidities.
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OBJECTIVES: To conduct an economic evaluation of an
open label, phase III randomized trial involving centers in
North America and Europe. METHODS: There were 239
and 235 patients in the liposomal doxorubicin (50mg/m2
every 4 weeks) and topotecan (1.5mg/m2 for 5 days every
3 weeks) arms, respectively. Overall median survival was
420 days and 397 days for liposomal doxorubicin and to-
potecan, respectively (hazard ratio  1.12 (90% CI
0.92,1.37; p  .34)). Because the outcomes were not clin-
ically different for the 2 groups, a cost minimization anal-
ysis was performed. Costs included were: study drug;
drug administration; and management of adverse events.
Actual mg of drug administered and frequency and sever-
ity of adverse events were obtained from the clinical trial.
Expert opinion was used to estimate the resources used in
the treating adverse events, and unit costs were based on
UK practice data. Further validation of the expert opinion
is currently underway. RESULTS: Severe (Grade III/IV)
toxicities were more frequent for liposomal doxorubicin
versus topotecan in terms of palmar-plantar erythrodyses-
thesia (PPE) (n  64 vs. 0), and stomatitis/pharyngitis (n 
32 vs. 2) but less frequent for thrombocytopenia (n  3
vs. 238), anemia (n  19 vs. 146), neutropenia (n  55
vs. 764) and fever (n  2 vs. 13). The average cost per pa-
tient was estimated to be EUR16,230 (95% CI 14,780 to
17,680) and EUR20,554 (95% CI 18,764 to 22,344) for
liposomal doxorubicin and topotecan, respectively. Per
patient cost for drug  administration were similar be-
tween the two groups, (EUR14,974 and EUR15,073); the
main differential in cost was management of anemia
(EUR407 and EUR2,219) and neutropenia (EUR57 and
EUR1,454) for the liposomal doxorubicin and topotecan
groups, respectively. CONCLUSIONS: In settings where
the current standard of care for platinum refractory or re-
sistant ovarian cancer is topotecan, liposomal doxorubi-
cin offers the potential for savings through reduction in
cost of adverse event management.
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Cost-utility analysis is rapidly becoming the standard
pharmacoeconomic measure in oncology. OBJECTIVE:
To compare paclitaxel (pac) and docetaxel (doc) in the
treatment of second line or greater metastatic breast can-
cer using a cost-utility analysis. METHODS: Utilities we
collected from 45 patients using eight modified Markov
modeled health states (Pharmacoeconomics, 1996;
60:504) describing metastatic breast cancer; the standard
gamble procedure was utilized to obtain utility. Costs
were collected prospectively from 31 patients in a single
outpatient center. Direct medical costs were collected
(e.g., all medications, physician/clinic/laboratory visits,
ER, hospitalizations, home health care, consultations,
special procedures, transfusions, phone calls, and miscel-
laneous) and costs were defined using Medicare reim-
bursement rates and AWP for drugs. Sensitivity analyses
are currently underway. RESULTS: The average cost per
cycle of chemotherapy was $4,298 and $2,869 for doc
and pac respectively. The mean utility score obtained
from patients was .78 and .76 for doc and pac respec-
tively. The utility scores suggest that doc offers 7.3 days
of perfect health when compared to pac. However, the
incremental cost-utility analysis (cost of doc  cost of
pac/QALY of doc  QALY of pac) indicates that the use
of doc costs $71,450 per Quality Adjusted Life Year
(QALY) when compared to pac. Another way to view
these results is that it costs $195.75 more per Quality Ad-
justed Day (QAD) to treat a patient with docetaxel.
CONCLUSIONS: Our results indicate that docetaxel is
more expensive ($4,298/cycle vs. $2,869/cycle) than pa-
clitaxel, and that metastatic breast cancer patients do not
perceive the drugs as being different (utility scores .76 for
pac and .78 for doc). This cost-utility analysis suggests
that the use of docetaxel over paclitaxel may not be justi-
fied in the treatment of metastatic breast cancer.
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OBJECTIVE: Chemotherapy-induced bone marrow tox-
icity is expensive because of the cost of managing compli-
cations of pancytopenia. Growth factors minimize these
complications. Economic analyses of growth factors typi-
cally focus on common, less serious outcomes, rather
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than on rare, serious outcomes. As a result, the samples
are too small to estimate the financial burden of less com-
mon outcomes; underestimation of the economic value of
these agents may occur. To illustrate, we examined the
cost of a less common, but serious outcome of chemo-
therapy, thrombocytopenia-related bleeding, in large and
small samples of cancer patients. METHOD: The cost of
1562 chemotherapy cycles in 612, randomly-chosen can-
cer patients was estimated from retrospective review of
medical and administrative databases. Cost was esti-
mated using a resource-based strategy (pharmaceuticals,
hospital and clinic costs, transfusions) from the pro-
vider’s perspective, in 1999 dollars. Twelve random,
10% samples of the cycles were selected, approximating
the size of most growth factor trials. Mean costs were
compared with two-tailed t-tests. RESULTS: Using the
entire sample, cycles with thrombocytopenia were more
expensive than those without ($7933 vs 4875, p 
0.0001). Cycles with bleeding were more expensive than
those without ($13,728 vs $7374, p  0.0001). They
were comparable in the costs of all inpatient and outpa-
tient services except monitoring ($538 vs $472, p 
0.01), transfusions to prevent bleeding ($1367 vs $758,
p  0.007), and bleeding treatment ($4702 vs $0, p 
0.0001). However, the cost of cycles with bleeding
(range: $8289–$16,277) was significantly higher than cy-
cles without bleeding (range: $5796–$8872) in only 5 of
the 12 small samples. CONCLUSIONS: The economic
impact of uncommon, but expensive outcomes should be
examined in samples large enough to permit calculation
of stable estimates of cost. The high cost of rare out-
comes such as bleeding will be better appreciated, as will
the importance of avoiding such episodes by preventing
thrombocytopenia.
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OBJECTIVES: In this study we compared outcomes and
costs between three treatments options (mastectomy
(MRM), breast conservation surgery with radiation (BC-
SRT), and breast conservation surgery only (BCSO)) for
elderly women with localized breast cancer. METHODS:
The sample was a national random sample from Medi-
care claims of 2,821 elderly women treated between
1992 to 1994 for localized breast cancer. Data on patient
preferences were collected in patient interviews con-
ducted in 1997. The outcomes studied were 5-year sur-
vival, Quality Adjusted Life Years (QALY), total costs
and cost/QALY. For each outcome we used univariate,
multivariate and instrumental variable analysis to com-
pare the differences between treatments. The instrumen-
tal variables used were geographic region, and distance to
nearest radiation facility. RESULTS: There were 1813
patients who received MRM, 704 who received BCSRT,
and 304 who received BCSO. The multivariate analysis
showed significantly higher survival for BCSRT relative
to MRM (4.21 vs. 4.13) and significantly higher QALYs
(3.50 vs. 3.45), but the IV analysis found an insignificant
difference opposite in sign. Costs were significantly
higher for BCSRT relative to MRM ($54,073 vs.
$37,327 in multivariate analysis). The cost-effectiveness
ratio of BCSRT relative to MRM is $334,920/QALY
(CI:$80,000 to NW) per QALY using multivariate esti-
mates and dominated using IV estimates. CONCLU-
SION: Survival and QALYs are statistically higher in tra-
ditional analyses of the BCSRT group relative to MRM,
but the IV analysis suggests an upward bias due to the se-
lection of healthier patients into BCSRT. This finding is
consistent with previous studies. Costs are unequivocally
higher in the BCSRT group suggesting BCSRT is not a
cost-effective option relative to MRM. Supplemental
analyses suggests that the presence of choice between
MRM and BCSRT raises the quality of life for all elderly
women independent of the choice that is made. Thus,
choice is costly but valuable.
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OBJECTIVE: This study assesses the health state prefer-
ences for adverse effects of chemotherapy on healthy
individuals. Time trade off (TTO), Standard Gamble
(SG), and Visual Analogue Scale (VAS) scores were com-
pared between side-effects and across two time points.
METHOD: A convenience sample of healthy pharmacy
students self-administered a questionnaire of TTO, SG
and VAS preferences for 12 different chemotherapy-related
side-effects ranging from anorexia to severe nausea. Re-
spondents completed the questionnaire on two separate
occasions separated by 2 weeks. RESULTS: Ninety-three
students completed at least one survey; 53 subjects com-
pleted both surveys (57%). The mean age of the sample
was 25 years; 21% were male. While no missing values
were seen in VAS questions, 23 missing responses were
noted in the TTO and 72 in the SG. TTO had the highest
test-retest correlation (ranging from 0.35 to 0.75) and
VAS had the lowest correlation (ranging from 0.29 to
0.65). The order of the preference measures was consis-
tent across nine of the twelve side-effects. The widest
